logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01

26. March 2020
|In Portfolio News
|By eazee-designstudio

First patient dosed in EVICTION trial evaluating ImCheck’s lead anti-cancer drug ICT01

26. March 2020
|In Portfolio News
|By eazee-designstudio

ImCheck Therapeutics has dosed the first patient in a Phase I/IIa clinical trial evaluating ICT01, a first-in-class gamma delta T cell-activatingmonoclonal antibody targeting the extracellular domain of Butyrophilin 3A. EVICTION (EValuation of ICT01 in Immuno-ONcology) is a first-in-human, two-part, open-label clinical trial to assess the safety, tolerability and activity of ICT01 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced, relapsed/refractory cancer, including both solid and hematologic tumors that express BTN3A.

  • Prev
  • Next

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences